Codexis extends process development collaboration with Merck
The initial agreement was signed in April 2007 and present agreement provides an extension to 2015. Merck will continue to use Codexis’ enzyme products to develop cost- and
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.